Heart failure hospitalizations are the primary driver of high heart failure costs in Spain, indicating that optimizing medical therapy could reduce the overall economic burden.
HF hospitalizations drive high costs in Spain; hypothesis-generating for therapy optimization, needs prospective confirmation before practice change.
HCRU and cost associated with HF are high in Spain, HF hospitalizations being the main determinant. Medication cost represented only a small proportion of total costs, suggesting that an optimization of HF therapy may reduce HF burden.
No takes yet. Share an insight, caveat, or question.
Escobar et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: